What is Vivid Genomics?
Vivid Genomics operates at the forefront of precision medicine, specifically targeting the high-stakes domain of dementia and Alzheimer's disease research. The company has developed a proprietary platform known as Genomic Biopsy, which integrates machine learning with genomic data to provide actionable insights into disease pathology. Their core offerings, AmyloidGB and ProgressionGB, serve as sophisticated diagnostic tools that facilitate precise patient stratification. By identifying amyloid plaque presence and forecasting disease progression, Vivid Genomics enables pharmaceutical developers to optimize clinical trial designs, thereby reducing failure rates and accelerating the path to therapeutic breakthroughs in neurology.
How much funding has Vivid Genomics raised?
Vivid Genomics has raised a total of $38K across 1 funding round:
Debt
$38K
Debt (2021): $38K with participation from PPP
Key Investors in Vivid Genomics
PPP
Public-Private Partnership
What's next for Vivid Genomics?
With this latest infusion of capital, Vivid Genomics is poised to scale its operational capacity and broaden the reach of its diagnostic suite. The strategic focus will likely shift toward deepening partnerships with global pharmaceutical leaders and expanding the clinical validation of its blood-based testing models. As the industry moves toward more personalized therapeutic interventions, the company's ability to provide granular, data-driven patient selection will be a key differentiator. Future growth will likely involve enhancing the predictive accuracy of their machine learning algorithms and potentially exploring new therapeutic areas within the broader neurodegenerative spectrum, ensuring long-term value creation for stakeholders and improved outcomes for patients.
See full Vivid Genomics company page
